SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence

Background. Over the last few years, the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) has increased substantially in medical practice due to their documented benefits in cardiorenal and metabolic health. In this sense, and in addit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Luis D'Marco, Valery Morillo, José Luis Gorriz, María K. Suarez, Manuel Nava, Ángel Ortega, Heliana Parra, Nelson Villasmil, Joselyn Rojas-Quintero, Valmore Bermúdez
Formato:	article
Lenguaje:	EN
Publicado:	Hindawi Limited 2021
Materias:	Diseases of the endocrine glands. Clinical endocrinology RC648-665
Acceso en línea:	https://doaj.org/article/2429d38f9c04442fa80e1693aa5bb47e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2429d38f9c04442fa80e1693aa5bb47e
record_format	dspace
spelling	oai:doaj.org-article:2429d38f9c04442fa80e1693aa5bb47e2021-11-22T01:10:31ZSGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence2314-675310.1155/2021/9032378https://doaj.org/article/2429d38f9c04442fa80e1693aa5bb47e2021-01-01T00:00:00Zhttp://dx.doi.org/10.1155/2021/9032378https://doaj.org/toc/2314-6753Background. Over the last few years, the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) has increased substantially in medical practice due to their documented benefits in cardiorenal and metabolic health. In this sense, and in addition to being used for glycemic control in diabetic patients, these drugs also have other favorable effects such as weight loss and lowering blood pressure, and more recently, they have been shown to have cardio and renoprotective effects with anti-inflammatory properties. Concerning the latter, the individual or associated use of these antihyperglycemic agents has been linked with a decrease in proinflammatory cytokines and with an improvement in the inflammatory profile in chronic endocrine-metabolic diseases. Hence, these drugs have been positioned as first-line therapy in the management of diabetes and its multiple comorbidities, such as obesity, which has been associated with persistent inflammatory states that induce dysfunction of the adipose tissue. Moreover, other frequent comorbidities in long-standing diabetic patients are chronic complications such as diabetic kidney disease, whose progression can be slowed by SGLT2i and/or GLP-1RA. The neuroendocrine and immunometabolism mechanisms underlying adipose tissue inflammation in individuals with diabetes and cardiometabolic and renal diseases are complex and not fully understood. Summary. This review intends to expose the probable molecular mechanisms and compile evidence of the synergistic or additive anti-inflammatory effects of SGLT2i and GLP-1RA and their potential impact on the management of patients with obesity and cardiorenal compromise.Luis D'MarcoValery MorilloJosé Luis GorrizMaría K. SuarezManuel NavaÁngel OrtegaHeliana ParraNelson VillasmilJoselyn Rojas-QuinteroValmore BermúdezHindawi LimitedarticleDiseases of the endocrine glands. Clinical endocrinologyRC648-665ENJournal of Diabetes Research, Vol 2021 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the endocrine glands. Clinical endocrinology RC648-665
spellingShingle	Diseases of the endocrine glands. Clinical endocrinology RC648-665 Luis D'Marco Valery Morillo José Luis Gorriz María K. Suarez Manuel Nava Ángel Ortega Heliana Parra Nelson Villasmil Joselyn Rojas-Quintero Valmore Bermúdez SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
description	Background. Over the last few years, the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) has increased substantially in medical practice due to their documented benefits in cardiorenal and metabolic health. In this sense, and in addition to being used for glycemic control in diabetic patients, these drugs also have other favorable effects such as weight loss and lowering blood pressure, and more recently, they have been shown to have cardio and renoprotective effects with anti-inflammatory properties. Concerning the latter, the individual or associated use of these antihyperglycemic agents has been linked with a decrease in proinflammatory cytokines and with an improvement in the inflammatory profile in chronic endocrine-metabolic diseases. Hence, these drugs have been positioned as first-line therapy in the management of diabetes and its multiple comorbidities, such as obesity, which has been associated with persistent inflammatory states that induce dysfunction of the adipose tissue. Moreover, other frequent comorbidities in long-standing diabetic patients are chronic complications such as diabetic kidney disease, whose progression can be slowed by SGLT2i and/or GLP-1RA. The neuroendocrine and immunometabolism mechanisms underlying adipose tissue inflammation in individuals with diabetes and cardiometabolic and renal diseases are complex and not fully understood. Summary. This review intends to expose the probable molecular mechanisms and compile evidence of the synergistic or additive anti-inflammatory effects of SGLT2i and GLP-1RA and their potential impact on the management of patients with obesity and cardiorenal compromise.
format	article
author	Luis D'Marco Valery Morillo José Luis Gorriz María K. Suarez Manuel Nava Ángel Ortega Heliana Parra Nelson Villasmil Joselyn Rojas-Quintero Valmore Bermúdez
author_facet	Luis D'Marco Valery Morillo José Luis Gorriz María K. Suarez Manuel Nava Ángel Ortega Heliana Parra Nelson Villasmil Joselyn Rojas-Quintero Valmore Bermúdez
author_sort	Luis D'Marco
title	SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
title_short	SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
title_full	SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
title_fullStr	SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
title_full_unstemmed	SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
title_sort	sglt2i and glp-1ra in cardiometabolic and renal diseases: from glycemic control to adipose tissue inflammation and senescence
publisher	Hindawi Limited
publishDate	2021
url	https://doaj.org/article/2429d38f9c04442fa80e1693aa5bb47e
work_keys_str_mv	AT luisdmarco sglt2iandglp1raincardiometabolicandrenaldiseasesfromglycemiccontroltoadiposetissueinflammationandsenescence AT valerymorillo sglt2iandglp1raincardiometabolicandrenaldiseasesfromglycemiccontroltoadiposetissueinflammationandsenescence AT joseluisgorriz sglt2iandglp1raincardiometabolicandrenaldiseasesfromglycemiccontroltoadiposetissueinflammationandsenescence AT mariaksuarez sglt2iandglp1raincardiometabolicandrenaldiseasesfromglycemiccontroltoadiposetissueinflammationandsenescence AT manuelnava sglt2iandglp1raincardiometabolicandrenaldiseasesfromglycemiccontroltoadiposetissueinflammationandsenescence AT angelortega sglt2iandglp1raincardiometabolicandrenaldiseasesfromglycemiccontroltoadiposetissueinflammationandsenescence AT helianaparra sglt2iandglp1raincardiometabolicandrenaldiseasesfromglycemiccontroltoadiposetissueinflammationandsenescence AT nelsonvillasmil sglt2iandglp1raincardiometabolicandrenaldiseasesfromglycemiccontroltoadiposetissueinflammationandsenescence AT joselynrojasquintero sglt2iandglp1raincardiometabolicandrenaldiseasesfromglycemiccontroltoadiposetissueinflammationandsenescence AT valmorebermudez sglt2iandglp1raincardiometabolicandrenaldiseasesfromglycemiccontroltoadiposetissueinflammationandsenescence
_version_	1718418327503634432

SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence

Ejemplares similares